Scribe Therapeutics (SCRE) Q3 2026 earnings summary

Executive summary

• Q3 collaboration revenue fell to $1.636M from $20.113M YoY as prior-period collaboration revenue did not recur; net loss was $9.863M versus net income of $1.472M.

• July IPO and concurrent Sanofi private placement generated $155.5M gross and ~$140.2M net proceeds; cash, cash equivalents and marketable securities reached $174.2M, projected to fund operations into H1 2029.

• STX-1150 Phase 1 enrollment continued, with initial single ascending dose data expected in H1 2027; the Sanofi collaboration expanded to include ELXR for an additional target.

Financial highlights

• Q3 collaboration revenue was $1.636M versus $20.113M in Q3 2025; nine-month revenue was $5.787M versus $42.136M.

• Q3 operating expenses declined 30% to $12.5M; R&D was $8.259M versus $14.421M, while G&A was $4.239M versus $3.531M.

• Nine-month operating expenses fell 33% to $38.5M; R&D decreased 36% to $28.4M and G&A decreased 22% to $10.1M.

• Nine-month net loss was $33.687M versus $11.857M; accumulated deficit was $191.4M at September 30, 2026.

• Nine-month operating cash use was $24.1M; investing provided $42.7M and financing provided $140.7M, increasing cash, cash equivalents and restricted cash by $159.3M.

Outlook and guidance

• Initial STX-1150 Phase 1 single ascending dose data on safety, tolerability and LDL-C activity are expected in H1 2027.

• Cash, cash equivalents and marketable securities are expected to fund planned operations and capital needs into H1 2029; the estimate depends on assumptions that may prove incorrect.

• Operating losses and expenses are expected to rise as STX-1150 advances clinically, STX-1200 and STX-1400 progress, and research, manufacturing and public-company costs expand.